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Presence of C-type natriuretic peptide in human kidney and urine. The
current study was undertaken to investigate the presence of CNP immu-
noreactivity in both human kidney and urine. Immunohistochemical
staining with an indirect immunoperoxidase method utilizing an antibody
which is 100% cross-reactive to both CNP-53 and CNP-22 was performed
on five human kidney specimens (three biopsies of normal cadaveric
donor kidneys and two of normal autopsy specimens). CNP immunoreac-
tivity was positive in proximal, distal and medullaiy collecting duct tubular
cells in a cytoplasmic and granular staining pattern. CNP immunoreactiv-
ity was also determined in the urine of five healthy volunteers utilizing a
sensitive and specific double-antibody radioimmunoassay with a mean
concentration of 10.8 1.0 pg/mI. With the utilization of high pressure
liquid chromatography, this immunoreactivity proved to be consistent with
both the low molecular weight form, CNP-22, as well as the high molecular
weight form, CNP-53. Urinary excretion of CNP was also measured in
normal subjects (N 5) and in patients with congestive heart failure(CHF, N = 6). CHF patients excreted over three times more CNP than
normals (27.2 2.8 vs. 8.7 0.81pg/mm, P < 0.004) despite no difference
between the two groups in plasma CNP concentrations (6.97 0.28 vs.
8.08 1.52 pg/mI, P = NS). This study demonstrates for the first time the
presence of CNP immunoreactivity in human kidney and suggests that
renal tubular cells may be an additional non-vascular site of synthesis for
this cardiorenal acting peptide. This study also demonstrates an increase
in urinary CNP excretion in congestive heart failure.
Atrial natriuretic peptide, brain natriuretic peptide (BNP) and
C-type natriuretic peptide (CNP) are a family of structurally
related but genetically distinct natriuretic peptides which mediate
their biological actions through a family of particulate guanylyl
cyclase receptors in the regulation of cardiorenal function [1].
CNP, a 22-amino acid peptide, is the newest member of this
natriuretic peptide system [2]. Studies have demonstrated that
ANP and BNP are ligands for a guanylyl cyclase coupled receptor,
the NPR-A receptor, while CNP is a specific ligand for a separate
guanylyl cyclase-coupled receptor termed the NPR-B receptor [1,
3]. All three natriuretic peptides bind to the NPR-C receptor
which does not Contain guanylyl cyclase and functions predomi-
nantly as a clearance receptor [4].
Though initially identified in porcine brain [2], CNP immuno-
reactivity recently has been found in human plasma and vascular
Received for publication October 28, 1993
and in revised form March 25, 1994
Accepted for publication March 28, 1994
© 1994 by the International Society of Nephrology
endothelial cells [5]. In recent studies, Suzuki et al [6] have
reported CNP synthesis in cultured rat renal cells, suggesting the
kidney may be a site for CNP production. In preliminary studies,
Dean and Greenwald [7] have reported that the gene transcript
for CNP is expressed in human kidney. To date, however, the
presence of CNP in the human kidney as well as in human urine
remains undefined. The objectives of this study were twofold. The
first was to investigate the presence of CNP immunoreactivity in
normal human kidney and urine. The second objective was to
compare the urinary excretion of CNP in normals to the excretion
of this peptide in patients with congestive heart failure.
Methods
Patients
Six patients with congestive heart failure (CHF) (NYHA class
II, N = 4 and III N = 2) and five normal subjects were included
in this study. The CHF group consisted of all men with a mean age
of 59 (range 44 to 72) while the control group consisted of four
men and one woman with a mean age of 30 (range 26 to 32). The
cause of CHF was ischemic cardiomyopathy in five and rheumatic
heart disease in one. All CHF patients were taking digoxin and an
angiotensin converting enzyme inhibitor. In addition, five of the
six were taking furosemide.
Informed consent was obtained from each patient and the study
protocol was approved by our institutional review board.
Tissue
Human kidney tissue was obtained from biopsy specimens of
normal cadaveric donor kidneys (N 3) and normal autopsy
specimens (N 2).
Urine
Urine samples were collected in a fasted state from congestive
heart failure patients (N = 6) and normal subjects (N 5) starting
with the second morning void and continuing for the next four
hours. Due to an inability to void after exactly four hours, the
urine collection was extended in one CHF patient to seven hours
and in one normal subject to six hours. All urine was collected on
ice and immediately frozen to —20°C after collection.
Plasma samples were drawn from an antecubital vein in a
seated position at the midpoint of the urine collection and
immediately cold centrifuged (4°C, 2500 rpm) and frozen to
—20°C.
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linmunohistochemical staining
The presence of CNP immunoreactivity was assessed utilizing a
two-stage immunohistochemical technique as previously reported
[5]. Briefly, paraffin embedded renal tissue was cut to a thickness
of six microns and placed on silanized slides. The slides were
incubated with 0.6% hydrogen peroxide in methanol for 20
minutes at room temperature to block endogenous peroxidase
activity, and then 5% normal goat serum was used to block
nonspecific protein binding sites before antibody was applied.
Sections were placed in a moist chamber for 18 to 24 hours at
room temperature with the primary antibody (rabbit anti-human
CNP, Peninsula Laboratory, Belmont, California, USA) at a
dilution of 1:1,600. Control slides were treated with normal dilute
rabbit serum. Sections were incubated with a goat anti-rabbit IgG
covalently linked to horseradish peroxidase and 3-amino-9-ethyl-
carbazole substrate for peroxidase visualization and were coun-
terstained with hematoxylin to enhance nuclear detail.
Radioimmunoassay (RU)
Plasma and urine samples were extracted by the Vycor glass
technique modified from the method of Guktowska et al [8].
Briefly, 1 ml of urine or plasma was gently mixed with 0.5 ml of
Vycor glass (Corning Glass Works, Corning, New York, USA)
suspension for one hour at 4°C. The Vycor was washed with water,
and the CNP was eluted from the Vycor with 60% acetone in 0.05
molar HC1. Eluates were concentrated on a savant and pellets
were resuspended in assay buffer for RIA. CNP immunoreactivity
was then determined utilizing a double-antibody RIA. A specific
antibody to human CNP-22 was used in the assay (Peninsula
Laboratory). As shown by Stingo et al [5] from our laboratory
recovery of CNP was 72 6% as determined by addition a
synthetic CNP to plasma. The lower limit of detection was 2
pg/tube. Intra-assay and inter-assay variability were both deter-
mined to be 5.2%. Cross-reactivity of the CNP-22 antibody with
CNP-53 was established by addition of synthetic CNP-53 (Penin-
sula Laboratory) to the CNP-22 assay at concentrations ranging
from 2 to 500 pg. The cross-reactivity was determined to be 97
6%. There was no cross-reactivity between the specific CNP-22
antibody and ANP, BNP, and endothelin. This was verified by
addition of synthetic ANP, BNP, and endothelin (Peninsula
Laboratory) to the CNP assay at concentrations ranging from 0.5
to 500 pg with no detectable immunoreactivity.
Reverse phase-high pressure liquid chromatography
The same urine samples collected for measurement of CNP
(CHF N = 6 and normals N = 5) were analyzed individually using
reverse phase HPLC with a Vydac C18 column (4.6 X 250 mm:
The Separations Group). The components of the HPLC system
were two pumps (model 114; Beckman Instruments Inc., San
Ramon, California, USA), an absorbance detector (model ABI
759A Applied Biosystems, Inc.), and an IBM PS2 50Z computer
with Beckman System Gold Chromatography software. The A
buffer was 0.1% trifluoroacetic acid and the B buffer was 80%
acetonitrile, 20% water, and 0.1% trifluoroacetic acid. The sepa-
ration was performed with a gradient of 5 to 70% B buffer in 60
minutes.
Urine and plasma creatinine concentrations were measured by
a Beckman Creatinine Analyzer 2.
Statistics
Concentrations of CNP immunoreactivity in human urine and
plasma as well as CNP excretion are expressed as the mean SE.
Comparisons between groups were performed by two-tailed,
unpaired Student's t-test.
Results
Figure 1 illustrates the immunohistochemical staining for CNP
in human renal tissue. There was positive staining in all tubular
segments including the proximal (Fig. 1A), distal (Fig. 1B), and
medullary collecting ducts (Fig. 1C), which was predominantly
cytoplasmic with granularity in all cells. The nonimmune control
of human renal tissue (Fig. 1D) illustrates minimal staining. There
was no staining within the glomeruli or the endothelial cells of the
renal vasculature.
CNP immunoreactivity was present in the urine and plasma of
all subjects. As shown in Table 1, plasma CNP concentrations
were not different between the CHF patients and normals (6.97
0.28 vs. 8.08 1.52, NS); however, urinary CNP excretion was
significantly higher in CHF patients compared to normals (27.2
4.2 vs. 8.7 0.81, P < 0.005). Even after correcting for differences
in glomerular filtration rates by expressing urinary CNP as the
ratio of CNP excretion to creatinine excretion, there was still a
significant difference between CHF patients and normals (0.28
0.03 vs. 0.11 0.03, P < 0.003).
Figure 2 reveals a representative reverse phase high pressure
liquid chromatography (RP-HPLC) profile for the CNP immuno-
reactivity measured in the urine from a normal individual. RP-
HPLC revealed two peaks, one corresponding to the high molec-
ular weight form, CNP-53, and another corresponding to the low
molecular weight form, CNP-22. This same pattern was also seen
in the urine from CHF patients.
Discussion
The present study demonstrates for the first time the presence
of CNP immunoreactivity in human kidney and urine. CNP
immunoreactivity by immunohistochemical staining showed CNP
to be present in the epithelial cells of all tubular segments. These
findings document yet another human tissue site for the presence
of CNP outside the CNS. Though initially thought to be present
only in the CNS, the current studies support the concept that CNP
is located and possibly produced in the kidney of several different
species [6, 7, 9, 10].
CNP has been identified in tissue homogenates of the rat
kidney by two separate groups [6, 9]. Furthermore, Suzuki et al [6]
have also demonstrated CNP mRNA in the rat kidney as well as
the production of CNP by an established rat renal cell line,
NRK-52E cells. Additionally, Nir et al have shown in preliminary
studies the presence of CNP in dog kidney by immunohistochem-
ical staining and the secretion of CNP by cultured opossum kidney
cells which express proximal tubular characteristics [10]. Also,
complimentary to our results is the preliminary finding of the gene
transcript for CNP in human kidney by Dean and Greenwald [7].
This group was also able to localize CNP mRNA in microdis-
sected nephron segments of the rat to the proximal convoluted
tubule, cortical collecting duct, and medullary thick limbs [7].
Taken together, these findings suggest that CNP may be produced
in the kidney by the epithelial cells of the proximal and distal
nephron.
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Fig. 1. Immunohistochemical staining of human kidney. A. Proximal tubule )< 1,000 (upper left) B. Distal convoluted tubule X 1,000 (upper right) C.
Outer medullary collecting duct (outer stripe) X 1,000 (lower left) IL Nonimmune control X 400 (lower right).
Normals (N = 5) CHF (N = 6) P value
Plasma CNP pg/mi 8.08 1.52 6.97 0.28 NS
Urine concentration pg/g 9.53 3.2 28.08 2.8 <0.002
of creatinine
CNP excretion mI/mm 8.71 0.81 27.18 4.2 <0.004
CNP/creatinine excretion 0.11 0.03 0.28 0.03 <0.003
All three receptors for the natriuretic peptides have been
identified in human tissue [11—141. The primary receptor that
mediates the biological actions of CNP is the NPR-B receptor [1].
In the rat kidney, Konrad et al [15] have visualized this receptor
by autoradiography, while Schulz et al [16] have reported the
presence of NPR-B mRNA by Northern blot hybridization. In
human kidney, Canaan-Kuhl et al [14] have demonstrated gene
expression for NPR-B by the polymerase chain reaction, and Suga
and co-workers [171 have been able to detect the presence of this
receptor by binding studies on cultured renal cells. Though the
role of CNP in human physiology continues to evolve, the
presence of both the peptide and receptor in human kidney
suggests a role for CNP at the renal level. Our finding of the
localization of CNP immunoreactivity to renal epithelial cells and
its absence in the endothelial cells of glomeruli and the renal
vasculature suggests that CNP may have a role in regulation of
tubular cell function. CNP has been shown to possess anti-
proliferative properties in cultured vascular smooth muscle cells
Table 1. Plasma concentrations and urinary excretion rates of CNP in
normal subjects and congestive heart failure patients CNP53 CNP-22
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0.2
Q)0C
0.1
0.0
60
Time, minutes
Fig. 2. Representative reverse phase-high pressure liquid chromatography of
immunoreactive CNP in human urine. Arrows indicate calibration points
for CNP-53 and CNP-22.
[18]. This certainly raises the issue of whether CNP could be a
growth regulator of tubular epithelial cells.
We have also shown the presence of CNP immunoreactivity in
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human urine which exists as both the high molecular weight form,
CNP-53, and the low molecular weight form, CNP-22. This observa-
tion is in accordance with Suzuki et al [6} who have shown that
CNP-53 is produced by cultured rat renal parenchymal cells. Though
Stingo et al [5] have shown CNP-53 to be present in extracts of
cultured human aortic endothelial cells, representing a possible
storage form and/or prohormone of CNP-22, only the low molecular
weight form, CNP-22, has been identified in human plasma. Thus,
urine contains an additional molecular form of CNP than is found in
plasma. This, in addition to the fact that CNP is the most rapidly
degraded of the natriuretic peptides by neutral endopeptidase [19],
an ectoenzyme abundant in proximal tubular brush border vesicles,
suggests that the CNP in human urine most likely represents renal
production rather than filtered peptide. Mean urinaty concentrations
for ANP and BNP in normal subjects have been reported to be 38.0
and 14.1 nglg of creatinine, respectively [20]. In this study we have
found mean urinaiy concentrations of CNP to be 9.5 .tglg of
creatinine which is 250 to 750 times the urinary concentrations of
ANP and BNP, concentrations much higher than would be expected
from only glomerular filtration. However, definitive proof rests on
measuring radioactive CNP in urine following an intravenous infu-
sion of labeled CNP.
To date, CNP has been shown to be vasorelaxant [21—23] and
anti-proliferative [18, 24] in vascular smooth muscle, but natriure-
sis has been observed only in the rat [2]. Its function in sodium
retaining states such as congestive heart failure is also undefined,
though Wei et al [25] have observed increased immunohistochem-
ical staining for CNP in ventricular myocardium of CHF patients
compared to normals, despite no difference between the two in
circulating plasma CNP concentrations. Our finding that urinary
excretion of CNP is significantly higher in CHF patients than
normal subjects is further evidence to suggest that CNP may
function in sodium retaining states. Further studies are necessary
to address this potential function.
In conclusion, there is now good evidence for the presence of
CNP in the human kidney by immunohistochemical staining and
in human urine by a sensitive radioimmunoassay. Our results
support the concept that CNP may be produced by the kidney,
where it could function in a paracrine/autocrine manner. In
addition, CNP excretion is elevated in CHF, suggesting a role in
sodium retaining disorders.
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